TY - JOUR
T1 - EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-ΚB andMKK7/JNK/AP-1 signaling
AU - Venkatesan, Balachandar
AU - Valente, Anthony J.
AU - Prabhu, Sumanth D.
AU - Shanmugam, Prakashsrinivasan
AU - Delafontaine, Patrice
AU - Chandrasekar, Bysani
N1 - Funding Information:
This work was supported in part by the NIH-NHLBI grant HL-86787 (BC), HL-70241 and HL-80682 (PD), and by award number 1101BX007080 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development (BC). The disclaimer that the contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government.
PY - 2010/10
Y1 - 2010/10
N2 - The transmembrane glycoprotein extracellular matrix metalloproteinase inducer (EMMPRIN), and the pleiotropic proinflammatory cytokine interleukin (IL)-18, play critical roles in myocardial remodeling, by inducing matrix degrading metalloproteinases (MMPs). Previously we showed that IL-18 induces EMMPRIN expression in cardiomyocytes via MyD88/IRAK4/TRAF6/JNK-dependent Sp1 activation. Here in reciprocal studies we demonstrate that EMMPRIN is a potent inducer of IL-18 transcription, protein expression and protein secretion in primary mouse cardiomyocytes. We show for the first time that EMMPRIN stimulates the activation of NF-ΚB, AP-1, CREB, and ATF-2 in cardiomyocytes, and induces IL-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-ΚB and MKK7/JNK/AP-1 signaling. Moreover, EMMPRIN induces robust time-dependent induction of various MMP mRNAs. EMMPRIN also induces the mRNA of TIMPs 1 and 3, but in a delayed fashion. These results suggest that IL-18-induced EMMPRIN expression may favor net MMP expression and ECM destruction, and thus identify both as potential therapeutic targets in countering adverse myocardial remodeling.
AB - The transmembrane glycoprotein extracellular matrix metalloproteinase inducer (EMMPRIN), and the pleiotropic proinflammatory cytokine interleukin (IL)-18, play critical roles in myocardial remodeling, by inducing matrix degrading metalloproteinases (MMPs). Previously we showed that IL-18 induces EMMPRIN expression in cardiomyocytes via MyD88/IRAK4/TRAF6/JNK-dependent Sp1 activation. Here in reciprocal studies we demonstrate that EMMPRIN is a potent inducer of IL-18 transcription, protein expression and protein secretion in primary mouse cardiomyocytes. We show for the first time that EMMPRIN stimulates the activation of NF-ΚB, AP-1, CREB, and ATF-2 in cardiomyocytes, and induces IL-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-ΚB and MKK7/JNK/AP-1 signaling. Moreover, EMMPRIN induces robust time-dependent induction of various MMP mRNAs. EMMPRIN also induces the mRNA of TIMPs 1 and 3, but in a delayed fashion. These results suggest that IL-18-induced EMMPRIN expression may favor net MMP expression and ECM destruction, and thus identify both as potential therapeutic targets in countering adverse myocardial remodeling.
KW - Cardiac hypertrophy
KW - Matrix metalloproteinases
KW - Myocardial failure
KW - Myocardial remodeling
KW - Proinflammatory cytokines
UR - http://www.scopus.com/inward/record.url?scp=77956176871&partnerID=8YFLogxK
U2 - 10.1016/j.yjmcc.2010.05.007
DO - 10.1016/j.yjmcc.2010.05.007
M3 - Article
C2 - 20538003
AN - SCOPUS:77956176871
SN - 0022-2828
VL - 49
SP - 655
EP - 663
JO - Journal of Molecular and Cellular Cardiology
JF - Journal of Molecular and Cellular Cardiology
IS - 4
ER -